Healthcare Industry News: cesium
News Release - June 28, 2006
IsoRay Medical Names Eric Knipfer Southeast Area Director as Company Expands Business Development Initiatives
RICHLAND, Wash.--(HSMN NewsFeed)--June 28, 2006--IsoRay Medical, Inc. has named Eric Knipfer Southeast Area Director as the company continues to expand its relationships with top physicians, clinics and hospitals across the United States, said IsoRay Chairman and CEO Roger Girard.IsoRay Medical, Inc. is a wholly owned subsidiary of a public company, IsoRay, Inc. ("IsoRay") (OTCBB: ISRY ). It is the sole manufacturer and distributor of cesium-131(TM), a powerful medical isotope currently used in brachytherapy for the treatment of prostate cancer.
"Eric's strong network of working relationships with physicians in the field of brachytherapy across the Southeast provides us with a wide range of business development opportunities," said Girard. "As an innovative industry veteran, we expect Eric to have a very positive impact in our sales in that region and beyond."
Prior to joining IsoRay, Knipfer was brachytherapy director for Prostate Services of America and Amertek Medical (both acquired by an industry leader) and has participated in the development of several "market leader" product platforms in the field of prostate brachytherapy. He is a past certified Radiation Safety Officer who also has an extensive background in radiation safety and distribution. He has helped start programs in over 80 hospitals and free standing surgery centers.
"cesium-131 has re-energized the prostate seed brachytherapy market," said Knipfer. "Leading physicians in the field who have used cesium-131 are impressed with its short half-life and high energy, which negate the long term co-morbidities seen with current isotopes available to the market. I'm particularly excited about joining the innovative team of industry leaders at IsoRay."
The cesium-131 isotope is currently being used in brachytherapy treatment for prostate cancer, which is the second leading cause of cancer deaths among men in the U.S. IsoRay Medical, Inc. was founded in 1998 and received Food & Drug Administration 510(k) clearance in March 2003 for treatment of any malignant disease including cancers of the head and neck, brain, breast, prostate and other organs.
Over 50 clinics offer cesium-131 as a fast and aggressive option for fighting prostate cancer. They include recently added sites in the New York City metro area, Pennsylvania, California, Florida and other locations. They join a list of notable medical centers that includes the Arnold Palmer Prostate Center at Eisenhower Lucy Curci Cancer Center in Palm Springs, the Duke University Health System and New York Presbyterian/Weill Cornell Medical Center.
For more information on IsoRay Medical or cesium-131, visit www.isoray.com or www.cesium131.com
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the cesium-131 brachytherapy seed, used to treat prostate and other cancers. The cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our cesium-131 seed, the level of market share our seed may attain, and all other statements in this release, other than historical facts, are forward-looking statements. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, and our ability to enforce our intellectual property rights, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Source: IsoRay Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
